Enzymes

HRas, also known as HRAS, belongs to the small GTPase superfamily, Ras family and is widely expressed. It functions in signal transduction pathways. HRas can bind GTP and GDP, and they have intrinsic GTPase activity. It undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS). FCSS is arare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities, tumor predisposition, skin and musculoskeletal abnormalities. Defects in HRAS also can cause congenital myopathy with excess of muscle spindles. HRAS deficiency may be a cause of susceptibility to Hurthle cell thyroid carcinoma. It has been shown that defects in HRAS can cause susceptibility to bladder cancer which is a malignancy

ACPP (Acid phosphatase, prostate; also PAP and ACP3) is a 48-52 kDa glycoprotein member of the histidine acid phosphatase family of enzymes. It exists as a 95-100 kDa nondisulfide-linked homodimer that hydrolyzes phosphate esters under low pH to generate free phosphate. ACPP is expressed by prostate epithelium and pain-detecting spinal cord neurons. In the spinal cord, ACPP dephosphorylates AMP.

Human beta -Glucuronidase (EC 3.2.1.31) encoded by the GUSB gene is a lysosomal hydrolase involved in the stepwise degradation of glucuronic acid-containing glycosaminoglycans that include heparan sulfate, chondroitin sulfate and hyaluronan. The enzyme is only active on the glucuronic acid of the non-reducing end. The native protein has been reported as a tetrameric glycoprotein composed of identical subunits. Mutations in the GUSB gene are linked to mucopolysaccharidosis type VII. Accumulation of partially degraded glycosaminoglycans, with glucuronic acid residues at the non-reducing termini, are usually found in the lysosomes of patients with the disease. It has also been reported that this enzyme may contribute to the depletion of chondroitin from cartilage and thereby facilitate the damage of joints in rheumatoid arthritis.

Recombinant Human Urokinase-Type Plasminogen Activator is a serine protease, which specifically cleaves the zymogen plasminogen to form the active enzyme plasmin. Urokinase-Type Plasminogen Activator is a potent marker of invasion and metastasis in many human cancers associated with breast, colon, stomach, bladder, brain, ovary and endometrium. Human Urokinase-Type Plasminogen Activator is initially synthesized as 431 amino acid precursor with a N-terminal signal peptide residues. The single chain molecule is processed into a disulfide-linked two-chain molecule. There exists two forms A chain, the long A chain contains an EGF-like domain that is responsible for binding of the uPA receptor. The B chain corresponds to the catalytic domain.

Recombinant human FGFR2C (Fibroblast Growth Factor Receptor 2C) protein corresponding to the extracellular domain, encompassing amino acids 22-377. This construct contains a C-terminal human IgG1 Fc domain, followed by an Avi-Tag™. This protein was affinity purified.

Recombinant human CERK (ceramide kinase), encompassing amino acids 1-537(end). This construct contains a C-terminal FLAG-tag and two mutations of interest (K298G and K303G). This protein was affinity purified.

Complex of recombinant human CDK9 (Cyclin-dependent kinase 9), full length, amino acids 2-372(end), and recombinant human CyclinK, full length, amino acids 2-354(end). The CDK9 construct contains an N-terminal GST tag followed by a PreScission protease cleavage site, while the CyclinK construct contains an N-terminal GST-tag followed by a thrombin cleavage site. The proteins were co-expressed and purified as a complex.

Human ANGPT2 full-length ORF (ADR83012.1, 1 a.a. - 496 a.a.) recombinant protein with GST tag at N-terminal.

Human FAR1 full-length ORF (AAH17377.1, 1 a.a. - 515 a.a.) recombinant protein with GST tag at N-terminal.